Physicists at MIT have introduced a technique to study the interior of an atom’s nucleus by relying on the atom’s own electrons as “messengers” inside a molecule.
In research published on October 23 in Science, the team precisely measured the…

Physicists at MIT have introduced a technique to study the interior of an atom’s nucleus by relying on the atom’s own electrons as “messengers” inside a molecule.
In research published on October 23 in Science, the team precisely measured the…

Physicists at MIT have introduced a technique to study the interior of an atom’s nucleus by relying on the atom’s own electrons as “messengers” inside a molecule.
In research published on October 23 in Science, the team precisely measured the…

LOS ANGELES (AP) — A big-screen adaptation of the popular anime “Chainsaw Man” has beaten out a biopic about the Boss and the horror sequel “Black Phone 2” to top the North American box office.
It’s the latest win for an anime film, less…

Pakistan army on Sunday said that five of its soldiers and 25 militants were killed during border clashes with Afghanistan.These attacks occurred while Afghan and Pakistani officials met in Istanbul amid a recent ceasefire agreement.“These…

A groundbreaking study is taking a fresh look at one of science’s oldest questions: how did life arise from nonliving material on early Earth? Researcher Robert G. Endres of Imperial College London has created a new mathematical framework…

On Saturday, Sydney Sweeney graced the red carpet for the premiere of her forthcoming film “Christy” during the AFI Fest 2025, clad in a soft pink custom Miu Miu gown.
Styled by Molly Dickson, the “Euphoria” star,…

PUBG and Subnautica 2 publisher Krafton has declared itself an “AI-first company”, announcing a move to “place AI at the centre of problem solving” via a “complete” company reorganisation.
The megacorp outlined its “transition to…

Signage for Novartis AG at a building in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.
Bloomberg | Bloomberg | Getty Images
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported, citing a person familiar with the matter.
A deal could be announced as early as Sunday, the report said.
Novartis and Avidity didn’t immediately respond to CNBC’s requests for comment.
Avidity specializes in developing an innovative class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates. RNA-based therapeutics are a relatively new class of medications that work by altering how genes are expressed to treat or prevent diseases.
The reported discussions come as Novartis ramps up its research and development division. The company earlier this year pledged to invest $23 billion to build out its U.S.-based infrastructure, which includes plans to construct a second R&D hub in San Diego.
The company has also struck two key deals with Anthos Therapeutics and Regulus Therapeutics this year to boost its development and manufacturing of cardiovascular and kidney disease drugs.
Avidity shares closed at $49.15 on Friday. The stock, which has a market capitalization of roughly $7.2 billion, is up nearly 70% since the beginning of the year. Novartis shares closed at $130.36 on Friday.
Read the complete Bloomberg News report here.